Osteogenesis imperfecta (OI) is the most common bone genetic disorder and it is
characterized by bone brittleness and various degrees of growth disorder. Clinical severity …

Osteogenesis imperfecta (OI) or “brittle bone disease” is currently best described as a group
of hereditary connective tissue disorders related to primary defects in type I procollagen, and …

ABSTRACT A decade ago our group had reported that osteotomy healing was commonly
delayed in children with moderate to severe osteogenesis imperfecta (OI) who were treated …

Context Patients with glucocorticoid-dependent Duchenne muscular dystrophy (DMD) have
increased fracture risk and reduced bone mineral density (BMD), often precipitating mobility …

Osteogenesis imperfecta: questions and answers : Current Opinion in Pediatrics Osteogenesis
imperfecta: questions and answers : Current Opinion in Pediatrics Log in or Register …

Objective: Bisphosphonates have been demonstrated to increase the bone mineral density
(BMD) of osteogenesis imperfecta (OI) patients. We aimed to compare the efficacy and …

Bisphosphonates can increase bone mineral density (BMD) in children with osteogenesis
imperfecta (OI). In this study of adults with OI type I, risedronate increased BMD at lumbar …

Treatment with zoledronic acid (ZA) over 2 years, among 33 children with osteogenesis
imperfecta (OI) and five Bruck syndrome cases, showed reduction in fracture rates, pain, and …

There are limited data on the use of bisphosphonate therapy for secondary osteoporoses in
childhood, and no previous reports of the use of zoledronic acid in this group. We report 20 …

Aim: To evaluate the safety and efficacy of 12 months of zoledronic acid (ZA) administered
every 6 months to children with osteoporosis. Methods: Retrospective cohort study of 27 …